Drugdocs | Evinacumab-dgnb

Drug updated on 3/28/2024

Dosage Form	Injection (intravenous; 345 mg/2.3 mL (150 mg/mL), 1,200 mg/8 mL (150 mg/mL))
Drug Class	Angiopoietin-like 3 inhibitors
Ongoing and Completed Studies	ClinicalTrials.gov

Indication

Indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia.

Evinacumab-dgnb (Evkeeza) is indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia.
Two systematic reviews/meta-analyses were reviewed that discussed Evkeeza's role in treating familial hypercholesterolemia by targeting different proteins involved in lipid metabolism.
The first document highlights evinacumab-dgnb among several protein-targeted drugs such as statins, ezetimibe, alirocumab, and evolocumab used for managing familial hypercholesterolemia.
In comparison to placebo treatments in randomized controlled trials (RCTs), evinacumab-dgnb significantly reduced LDL-C levels along with triglycerides while also decreasing high-density lipoprotein cholesterol (HDL-C).
According to the second study from a meta-analysis of RCTs published between January 2000 and November 2020, there was no significant difference observed between the incidence of at least one treatment emergent adverse events when comparing Evkeeza with placebos.
This suggests that despite its effectiveness in reducing LDL-C levels alongside triglycerides and HDL-C without any significant adverse effects noted during these studies; hence it can be considered a viable therapeutic strategy for managing hypercholesterolemia according to these documents reviewed.

Document Title	Year	Source
Evkeeza (evinacumab-dgnb) Prescribing Information.	2023	Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Document Title	Year	Source
The promising novel therapies for familial hypercholesterolemia.	2022	Journal of Clinical Laboratory Analysis
Efficacy and safety of evinacumab for the treatment of hypercholesterolemia: a meta-analysis.	2021	Journal of Cardiovascular Pharmacology